基本信息
浏览量:247
职业迁徙
个人简介
The overall goal of my research is to advance the integration of immunotherapy within comprehensive cancer care, as a complementary modality to surgery, chemo and radiotherapy. My group develops new methods of using ex vivo-educated dendritic cells, DC-activated T cells, combinatorial adjuvants and checkpoint blockers, to promote selectively accumulation of type-1 immune cells (CTLs, Th1 and NK cells) in tumor lesions, without amplifying pre-existing Treg- and MDSC responses, in order to enhance local immune surveillance and enhance overall therapeutic outcomes. Our current projects include:
Development and clinical evaluation of therapeutic vaccines involving different subsets of “polarized” DCs (colorectal cancer, ovarian cancer, prostate cancer, melanoma, hematologic malignancies)
Development and clinical evaluation of adoptive T cell therapies (ACT) using ex vivo-induced polyclonal CTLs (ovarian- & colorectal cancers and melanoma)
Development and clinical evaluation of combinatorial approaches to enhance the effectiveness of vaccines, ACT and checkpoint blockers, but reprogramming tumor microenvironments for enhanced CTL infiltration and modulating intratumoral expression of PD-L1, PD-L2 and other checkpoints (colorectal cancer, ovarian cancer, prostate cancer, melanoma, bladder cancer, HPV-associated cancers)
Development of combinatorial adjuvants to modulate DC functions in situ
Counteracting cancer-related immunosuppressive mechanisms and their use in transplantation and autoimmunity
Role of the immune system in the effectiveness of oncolytic virotherapies
Role of the immune system in the effectiveness of chemotherapy and radiotherapy of cancer
Interplay between psychologic stress and cancer immunity These interdisciplinary projects involving multiple clinical and laboratory teams, have been advanced as parts of the as multiple NIH-, DOD-, pharma and biotech-funded grants and program projects (single- and multi-institution P01s and P50/SPOREs; where I have been serving as the overall PI, overall co-PI or a Project Leader) and focusing on the therapy of melanoma, colon cancer, prostate cancer, ovarian cancer, and hematologic malignancies. Our current work includes phase I/II and phase II clinical testing of the resulting paradigms and methods in cancer patients, and development of similar treatments for patients with premalignant lesions and chronic infections resistant to standard forms of treatment.
研究兴趣
论文共 389 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Bowen Dong,Nataša Obermajer,Takemasa Tsuji,Junko Matsuzaki, Cindy Bonura,Henry Withers,Mark Long,Colin Chavel,Scott H. Olejniczak, Hans Minderman,Robert P. Edwards,Walter J. Storkus,
Cancer Researchno. 6_Supplement (2024): 3966-3966
Jessica N. Filderman,Jennifer L. Taylor,Jianmin Wang, Yali Zhang,Prashant Singh,Mark A. Ross,Simon C. Watkins, Ayah Nedal Al Bzour,Lilit Karapetyan,Pawel Kalinski,Walter J. Storkus
Daniel Alvarado, Jennifer Peresie, Adam Brinkman, Cheryl Allen,Weijian Jiang,Pawel Kalinski, Tiffany Tanaka,Elizabeth Griffiths, Michael Nemeth
Cancer Researchno. 6_Supplement (2024): 6744-6744
Shipra Gandhi,Mateusz Opyrchal, Cayla Ford, Ronald Slomba,Kristopher Attwood,Tracey O'Connor,Ellis Levine,Pawel Kalinski
CANCER RESEARCHno. 5 (2023)
引用0浏览0引用
0
0
Naoki Umemura, Jianzhong Zhu, Yvonne K. Mburu,Adriana Forero,Paishiun N. Hsieh,Ravikumar Muthuswamy,Pawel Kalinski,Robert L. Ferris,Saumendra N. Sarkar
crossref(2023)
crossref(2023)
Ravikumar Muthuswamy, Erik Berk, Beth Fallert Junecko,Herbert J. Zeh,Amer H. Zureikat,Daniel Normolle,The Minh Luong,Todd A. Reinhart,David L. Bartlett,Pawel Kalinski
crossref(2023)
crossref(2023)
International journal of molecular sciencesno. 13 (2023): 10847-10847
引用0浏览0WOS引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn